No Evidence of Pritelivir Resistance Among Herpes Simplex Virus Type 2 Isolates After 4 Weeks of Daily Therapy

Background. Pritelivir is a novel helicase-primase inhibitor in clinical development for treatment of herpes simplex virus type 2 (HSV-2) infections. In preclinical work, resistance-mediating mutations were identified in the HSV-2 genome at 3 loci in the UL5 gene and 1 locus in UL52. Methods. To eva...

Descripción completa

Detalles Bibliográficos
Autores principales: Edlefsen, Paul T., Birkmann, Alexander, Huang, Meei-Li, Magaret, Craig A., Kee, Jia Jin, Diem, Kurt, Goldner, Thomas, Timmler, Burkhard, Stoelben, Susanne, Ruebsamen-Schaeff, Helga, Zimmermann, Holger, Warren, Terri, Wald, Anna, Corey, Lawrence
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2016
Materias:
Major Articles and Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918824/
https://www.ncbi.nlm.nih.gov/pubmed/27056950
http://dx.doi.org/10.1093/infdis/jiw129

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918824/
https://www.ncbi.nlm.nih.gov/pubmed/27056950
http://dx.doi.org/10.1093/infdis/jiw129

Ejemplares similares